Physician profile
Grace M Obrien
NPI 1093702003
$7,536.55
in general payments reported to CMS, 2019-2025
67 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $977 · 2021: $1,604 · 2022: $1,167 · 2023: $848 · 2024: $1,085 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.90 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.16 | 2019-2025 | |
| Amgen INC. | $797.22 | 2019-2025 | Evenity, Prolia, Tavneos |
| Astrazeneca Pharmaceuticals LP | $449.76 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Amarin Pharma, INC. | $410.90 | 2020-2022 | |
| Astellas Pharma US INC | $407.62 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $377.08 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $369.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.51 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $256.58 | 2019-2025 | Wegovy, Rivfloza, Ozempic |
| Pfizer INC. | $243.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $183.55 | 2019-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $147.26 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $132.66 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $131.54 | 2019-2025 | |
| Allergan, INC. | $118.70 | 2020 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.